Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-874/Human monoclonal antibody against IL-12 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-874 200 mg weekly | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| ABT 874 QOW | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-874/Human monoclonal antibody against IL-12 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Age between 18 and 55 years * Diagnosis of active relapse within 12 months of screening. * At least one relapse within 12 months of screening. * Must be able to walk at least 65 feet with or without assistance * Off Copaxone or interferon therapy for two months prior to screen...
ABT-874 is an investigational drug being studied for the treatment of psoriasis, including moderate to severe chronic plaque psoriasis. It has also been investigated for use in multiple sclerosis. The drug is in Phase 3 clinical development and is not yet approved by regulatory authorities.
ABT-874 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. AbbVie is conducting clinical trials to evaluate the safety and efficacy of ABT-874 in patients with moderate to severe plaque psoriasis.
ABT-874 is in Phase 3 clinical development. Multiple Phase 3 trials have been completed, including studies comparing ABT-874 to placebo and to etanercept in patients with moderate to severe chronic plaque psoriasis. The drug remains investigational and has not received FDA approval.
ABT-874 has been studied in several completed Phase 3 trials. NCT00570986 compared two dosing regimens of ABT-874 to placebo in 1,465 patients with plaque psoriasis. NCT00626002 was an open-label continuation study in 2,301 patients with moderate to severe psoriasis. NCT00691964 and NCT00710580 compared ABT-874 to etanercept and placebo in patients with chronic plaque psoriasis.
ABT-874 is also known as briakinumab. It is an investigational monoclonal antibody being developed by AbbVie for the treatment of moderate to severe plaque psoriasis. The drug has been evaluated in Phase 3 clinical trials, but it is not currently approved for any indication.